Статья
Первичная профилактика хронических неинфекционных заболеваний и ацетилсалициловая кислота: неоднозначность мнений
Хронические неинфекционные заболевания (заболевания сердечно-сосудистой системы, бронхолегочной системы, онкологические заболевания, сахарный диабет) – в настоящее время самая распространенная причина смерти в мире, среди которых ведущими являются сердечно-сосудистые заболевания (ССЗ). Именно поэтому одна из ключевых задач врача состоит не только в лечении, но и в профилактике заболеваний. Ацетилсалициловая кислота (АСК) рассматривается как один из эффективных лекарственных препаратов для вторичной профилактики ССЗ, при этом ее применение в первичной профилактике до настоящего времени является предметом обсуждения. Результаты многих исследований по изучению АСК неоднозначны. Имеются данные, свидетельствующие, что применение АСК у пациентов с высоким 10-летним риском развития ССЗ в возрасте от 40 до 70 лет и низким риском возникновения кровотечений способно уменьшить частоту возникновения ССЗ. Кроме того, рассматривается назначение АСК пациентам с высоким и средним риском развития ССЗ.
1. Shalnova S.A., Drapkina O.M. The Trends of Cardiovascular and Cancer Mortality in Russian Men and Women from 2000 to 2016 years. Rational Pharmacotherapy in Cardiology. 2019;15(1):77–83.. DOI: 10.20996/1819-6446-2019-15-1-77-83
2. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiology Biomarkers & Prevention. 2016;25(1):16–27. DOI: 10.1158/1055-9965.EPI-15-0578
3. Wilson L, Bhatnagar P, Townsend N. Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983–2013: joinpoint regression analysis. Population Health Metrics. 2017;15(1):23. DOI: 10.1186/s12963-017-0141-5
4. Federal State Statistics Service. Health in Russia. 2017. Statistical book. -M.: Rosstat;2017. - 170 p.. ISBN 978-5-89476-448-1
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. European Journal of Cardiovascular Prevention and Rehabilitation. 2009;16(2):121–37. DOI: 10.1097/HJR.0b013e3283294b1d
6. Galyavich A.S., Khairullin R.N., Baleeva L.V., Sleiter M., Akimova S.V., Galimzyanov A.F. et al. Risk factors of coronary artery disease in 27425 outpatients. Russian Journal of Cardiology. 2019;24(6):23–6.. DOI: 10.15829/1560-4071-2019-6-23-26
7. Balanova Yu.A., Shalnova S.A., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Evstifeeva S.E. et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450–66.. DOI: 10.20996/1819-6446-2019-15-4-450-466
8. Starodubov V.I., Dvornikov A.S., Shevchenko A.G., Lopakov K.V. Prospects for earlier detection of diseases based on the results of the survey of Internet users about their attitude to prevention. Social aspects of public health. 2011; 3 (19):1-13..
9. Mekaj A, Mekaj Y, Daci F. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Therapeutics and Clinical Risk Management. 2015;11:1449–56. DOI: 10.2147/TCRM.S92222
10. Paseban M, Marjaneh RM, Banach M, Riahi MM, Bo S, Sahebkar A. Modulation of microRNAs by aspirin in cardiovascular disease. Trends in Cardiovascular Medicine. 2019;S1050173819301148.. DOI: 10.1016/j.tcm.2019.08.005
11. Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention. Journal of the American College of Cardiology. 2014;64(3):319–27. DOI: 10.1016/j.jacc.2014.03.049
12. Romaine SPR, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015;101(12):921–8. DOI: 10.1136/heartjnl-2013-305402
13. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine. 2018;379(16):1529–39. DOI: 10.1056/NEJMoa1804988
14. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLOS ONE. 2016;11(8):e0160046. DOI: 10.1371/journal.pone.0160046
15. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315–81. DOI: 10.1093/eurheartj/ehw106
16. Poriadin G.V. Allergy and immunopathology (immune mechanisms of formation, principles of therapy). -M.: VUNMTS MZ RF;1999. - 282 p.. ISBN 978-5-89004-087-9
17. Rossini R, Iorio A, Pozzi R, Bianco M, Musumeci G, Leonardi S et al. Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). Circulation: Cardiovascular Interventions. 2017;10(2):e004368. DOI: 10.1161/CIRCINTERVENTIONS.116.004368
18. Hermans MAW, van der Vet SQA, van Hagen PM, van Wijk RG, van Daele PLA. Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The results of a double-blind, placebo-controlled challenge study. Allergy. 2018;73(10):2055–62. DOI: 10.1111/all.13445
19. Lichtenberger LM, Burge S. Aspirin use and the risk of malignant melanoma. Journal of the American Academy of Dermatology. 2019;80(1):e13. DOI: 10.1016/j.jaad.2018.07.065
20. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18(1):288. DOI: 10.1186/s12885-018-4156-5
21. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–832. DOI: 10.1161/STR.0000000000000046
22. Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology. 2019;42(5):498–505. DOI: 10.1002/clc.23164
23. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486
24. Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2017;135(7):659–70. DOI: 10.1161/CIRCULATIONAHA.116.025760
25. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036–46. DOI: 10.1016/S0140-6736(18)31924-X
26. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine. 2018;379(16):1519–28. DOI: 10.1056/NEJMoa1803955
27. Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2016;164(12):804–13. DOI: 10.7326/M15-2113
28. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine. 2018;379(16):1509–18. DOI: 10.1056/NEJMoa1805819
29. Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. The Lancet. 2018;392(10145):387–99. DOI: 10.1016/S0140-6736(18)31133-4
30. Bibbins-Domingo K, on behalf of the U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2016;164(12):836–45. DOI: 10.7326/M16-0577
31. Kunadian V, Chan D, Ali H, Wilkinson N, Howe N, McColl E et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2). BMJ open. 2018;8(5):e020713. DOI: 10.1136/bmjopen-2017-020713
32. Kunadian V, Wilson N, Stocken DD, Ali H, McColl E, Burns G et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Research. 2019;5(3):00110–2019. DOI: 10.1183/23120541.00110-2019